Philippe Knoche

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano Recyclage SAS engages in the production and transformation of nuclear materials. The company is based in La Hague, France. The French company is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Framatome, Inc. is a nuclear energy company based in Lynchburg, VA. Michael W. Rencheck has been the CEO of the company since 2009. The company manufactures and installs nuclear steam supply systems. Framatome, Inc. is a subsidiary of Framatome, a company ultimately controlled by the Government of France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Mining SA wholesales ores and metals. The company is based in Courbevoie, France. The French company is a subsidiary ultimately controlled by the Government of France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Orano Cycle SA provides nuclear fuel cycle services. It specializes in uranium mining conversion and enrichment. The company is headquartered in Chatillon, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.